Cargando…
SARS-CoV-2 infections in 165 countries over time
Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413603/ https://www.ncbi.nlm.nih.gov/pubmed/34487852 http://dx.doi.org/10.1016/j.ijid.2021.08.067 |
_version_ | 1783747672152211456 |
---|---|
author | Louca, Stilianos |
author_facet | Louca, Stilianos |
author_sort | Louca, Stilianos |
collection | PubMed |
description | Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and different testing strategies. Methods: This study uses death count statistics, age-dependent infection fatality risks, and stochastic modeling to estimate the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among adults (aged 20 years or older) in 165 countries over time, from early 2020 until June 25, 2021. The accuracy of the approach is confirmed through comparison with previous nationwide seroprevalence surveys. Results: The estimates presented reveal that the fraction of infections that are detected vary widely over time and between countries, and hence confirmed cases alone often yield a false picture of the pandemic. As of June 25, 2021, the nationwide cumulative fraction of SARS-CoV-2 infections (cumulative infections relative to population size) was estimated as 98% (95% confidence interval [CI] 93–100%) for Peru, 83% (95% CI 61–94%) for Brazil, and 36% (95% CI 23–61%) for the United States. Conclusions: The time-resolved estimates presented expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 165 countries. |
format | Online Article Text |
id | pubmed-8413603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84136032021-09-03 SARS-CoV-2 infections in 165 countries over time Louca, Stilianos Int J Infect Dis Article Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases because of a large fraction of asymptomatic infections and different testing strategies. Methods: This study uses death count statistics, age-dependent infection fatality risks, and stochastic modeling to estimate the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among adults (aged 20 years or older) in 165 countries over time, from early 2020 until June 25, 2021. The accuracy of the approach is confirmed through comparison with previous nationwide seroprevalence surveys. Results: The estimates presented reveal that the fraction of infections that are detected vary widely over time and between countries, and hence confirmed cases alone often yield a false picture of the pandemic. As of June 25, 2021, the nationwide cumulative fraction of SARS-CoV-2 infections (cumulative infections relative to population size) was estimated as 98% (95% confidence interval [CI] 93–100%) for Peru, 83% (95% CI 61–94%) for Brazil, and 36% (95% CI 23–61%) for the United States. Conclusions: The time-resolved estimates presented expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 165 countries. The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-10 2021-09-03 /pmc/articles/PMC8413603/ /pubmed/34487852 http://dx.doi.org/10.1016/j.ijid.2021.08.067 Text en © 2021 The Author Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Louca, Stilianos SARS-CoV-2 infections in 165 countries over time |
title | SARS-CoV-2 infections in 165 countries over time |
title_full | SARS-CoV-2 infections in 165 countries over time |
title_fullStr | SARS-CoV-2 infections in 165 countries over time |
title_full_unstemmed | SARS-CoV-2 infections in 165 countries over time |
title_short | SARS-CoV-2 infections in 165 countries over time |
title_sort | sars-cov-2 infections in 165 countries over time |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413603/ https://www.ncbi.nlm.nih.gov/pubmed/34487852 http://dx.doi.org/10.1016/j.ijid.2021.08.067 |
work_keys_str_mv | AT loucastilianos sarscov2infectionsin165countriesovertime |